Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Vildagliptin + Metformin

Fixed-dose combination: DPP-4 inhibitor plus biguanide

ATC code: A10BD08(Vildagliptin and metformin)

Updated · Methodology

Indications

A

Type 2 diabetes mellitus

Second line

Type 2 diabetes in adults with above target (usually <7%, <7.5–8% in older patients) on metformin monotherapy. Per / 2024 and redGDPS 2024, DPP-4 + metformin is one second-line option when ASCVD, HF, or CKD is absent (otherwise GLP-1 RA or SGLT2 inhibitors take priority). Dose: 50/850, 50/1000 mg twice daily with meals. Check HbA1c at 3 months. Combination strength – weight-neutral and low hypoglycemia risk.

Sources

  1. AEMPS: Ficha técnica de Vildagliptina (2024)
  2. ADA/EASD: Management of Hyperglycaemia in Type 2 Diabetes (2022)

ICD-10: E11 · ICD-11: 5A11

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

D

Anti-aging and longevity

Not recommended

Metformin in fixed-dose combinations is marketed as an anti-aging drug that extends lifespan in healthy adults. In 2026 the principal TAME trial is still ongoing with no results yet. In people without diabetes or prediabetes, metformin is not approved by AEMPS, , or . Additional risks include B12 deficiency (6–30% on long-term use), lactic acidosis during dehydration, and GI side effects. If prescribed for longevity without a diagnosis of type 2 diabetes or prediabetes ( <5.7%), consider getting a second opinion.

Sources

  1. AEMPS: Ficha técnica de Vildagliptina (2024)
  2. Cochrane: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases (2012)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Vildagliptin inhibits DPP-4 and raises endogenous GLP-1 and GIP, enhancing glucose-dependent insulin secretion and suppressing glucagon. Metformin lowers hepatic gluconeogenesis, increases peripheral insulin sensitivity, and slightly reduces intestinal glucose absorption. Additive effect: about -0.7% from DPP-4 on top of metformin.

Safety

Contraindications

  • Hypersensitivity
  • Type 1 diabetes
  • Diabetic ketoacidosis
  • Severe hepatic impairment (ALT >3× ULN)
  • Severe renal impairment (CrCl <30)
  • Acute conditions with renal risk (dehydration, shock, sepsis)
  • Acute or chronic hypoxic disease (HF class III-IV, respiratory failure)
  • Acute alcohol intoxication, chronic alcoholism

Serious adverse effects

  • Lactic acidosis (rare, mainly with dehydration or AKI)
  • Hepatotoxicity (vildagliptin)
  • Acute pancreatitis
  • Severe skin reactions (bullous pemphigoid from DPP-4 inhibitors)

Common adverse effects

  • Nausea, diarrhea, metallic taste (metformin)
  • Headache
  • Nasopharyngitis
  • Dizziness
  • Hypoglycemia when combined with sulfonylurea or insulin

Pregnancy: can you take Vildagliptin + Metformin?

Metformin is permitted in pregnancy for type 2 diabetes or gestational diabetes (per ADA 2024 and SEGO 2023, insulin remains first-line). Vildagliptin is not studied in pregnancy – switch to insulin.

Breastfeeding: can you take Vildagliptin + Metformin?

Metformin is compatible with breastfeeding (RID 0.28–0.65%, Hale L1). No milk data for vildagliptin – in nursing women, use metformin monotherapy or insulin instead of the DPP-4 combination.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Monitoring

every 3–6 months. ALT baseline and at 3, 6, 12 months (vildagliptin rarely causes hepatotoxicity). Vitamin B12 every 1–2 years on long-term metformin. Creatinine every 6–12 months.

Timing and administration

Take with meals to reduce GI side effects from metformin. Pause during AKI, shock, contrast studies, or major surgery (lactic acidosis risk).

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Vildagliptin + Metformin used for?

Vildagliptin + Metformin is evaluated for the following indications with varying evidence strength: Type 2 diabetes mellitus (evidence tier A), Anti-aging and longevity (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Vildagliptin + Metformin?

Common side effects of Vildagliptin + Metformin (≥ 1 in 100): Nausea, diarrhea, metallic taste (metformin), Headache, Nasopharyngitis, Dizziness, Hypoglycemia when combined with sulfonylurea or insulin. See the Safety section for uncommon and serious reactions.

Is Vildagliptin + Metformin safe during pregnancy?

Metformin is permitted in pregnancy for type 2 diabetes or gestational diabetes (per ADA 2024 and SEGO 2023, insulin remains first-line). Vildagliptin is not studied in pregnancy – switch to insulin.

Is Vildagliptin + Metformin compatible with breastfeeding?

Metformin is compatible with breastfeeding (RID 0.28–0.65%, Hale L1). No milk data for vildagliptin – in nursing women, use metformin monotherapy or insulin instead of the DPP-4 combination.

Who should not take Vildagliptin + Metformin?

Vildagliptin + Metformin is contraindicated in: Hypersensitivity; Type 1 diabetes; Diabetic ketoacidosis; Severe hepatic impairment (ALT >3× ULN); Severe renal impairment (CrCl <30). Full list in the Safety section.

Other drugs in this group

Dapagliflozin, Empagliflozin, Glibenclamide, Gliclazide, Insulin detemir, Linagliptin, Semaglutide, Glimepiride